Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicapone phase 3 trial in Parkinson's disease patients with end-of-dose motor fluctuations
ChiCTR2300069899Phase 3Completed
- Sponsor
- Ruijin Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Change from baseline to Weeks 14 to 16 in absolute OFF time recorded in subject diaries. Started Mar 2023; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2300069899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069899.